首页> 美国卫生研究院文献>Cancer Research and Treatment : Official Journal of Korean Cancer Association >Hyperammonemic Encephalopathy Mimicking Ornithine Transcarbamylase Deficiency in Fibrolamellar Hepatocellular Carcinoma: Successful Treatment with Continuous Venovenous Hemofiltration and Ammonia Scavengers
【2h】

Hyperammonemic Encephalopathy Mimicking Ornithine Transcarbamylase Deficiency in Fibrolamellar Hepatocellular Carcinoma: Successful Treatment with Continuous Venovenous Hemofiltration and Ammonia Scavengers

机译:纤维素肝细胞癌中的鸟氨酸转基氨基甲酶缺乏症的高血肿性脑病:用连续的血管血液过滤和氨清除剂成功治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver cancer affecting adolescents and young adults without any pre existing liver disease. Hyperammonemic encephalopathy (HAE) is a serious paraneoplastic syndrome, and several cases of HAE have been reported in patients with FLHCC. This condition is rare; hence, there are currently no management guidelines for cancer-related HAE. Herein, we report a case of an 18-year-old man with advanced FLHCC who developed HAE during the first course of chemotherapy consisting of cisplatin, doxorubicin, 5-fluorouracil, and interferon-α. He was successfully treated with continuous venovenous hemofiltration, sodium benzoate, sodium phenylbutyrate, and amino acid supplementation for HAE. After the second course of chemotherapy, he underwent surgery, and thereafter, his ammonia levels were normal without any ammonia scavenger therapy. Treatments for HAE described here will be helpful for this rare, but serious metabolic complication of FLHCC and could partially applied to HAE related to any malignancies.
机译:纤维素肝细胞癌癌(FLHCC)是一种罕见的肝癌,影响青少年和年轻成年人,没有任何预先存在的肝病。高血肿性脑病(HAE)是一种严重的坐标性综合征,并在FLHCC患者中报道了几例HAE。这种情况很少见;因此,目前没有癌症相关的HAE的管理指南。在此,我们举报了一个18岁男性的案例,具有高级FLHCC,在第一种化疗过程中开发了HAE,由顺铂,多柔比蛋白,5-氟尿嘧啶和干扰素-α组成。他成功地用连续的血管血液过滤,苯甲酸钠,苯基丁酯和HAE的氨基酸补充剂治疗。在第二课程化疗后,他接受了手术,此后,他的氨水量正常,没有任何氨清除剂治疗。这里描述的Hae治疗将有助于这种罕见,但对FLHCC的严重代谢并发症,可以部分地应用于与任何恶性肿瘤相关的HAE。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号